MedTrace Logo

Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure

NCT01187836 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-07-11

No results posted yet for this study

Summary

In this study, TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure to learn about the effects of TRV120027. The results of this study will help choose the proper range of TRV120027 doses to use in future research studies involving patients with acute decompensated heart failure.

Conditions

Interventions

DRUG

TRV120027

Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.

DRUG

Placebo

Placebo administered for 14 hours.

Sponsors & Collaborators

  • Trevena Inc.

    lead INDUSTRY

Principal Investigators

  • David G Soergel, M.D. · Trevena Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States
  • Czechia
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187836 on ClinicalTrials.gov